Common Stock

Common Stock

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
wasinington,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to

10/24/2022

10/24/2022

OMB APPROVAL

OMB Number: 3235-0287

Section 16. For obligations may Instruction 1(b)	y continue. See		Filed pursua	ant to Section 16(a) ection 30(h) of the In	of the So	ecuriti	es Exchange Ac	et of 1934 40		ll ll	stimated average bu ours per response:	o.5
1. Name and Address of Reporting Person* ARCH Venture Partners X, LLC (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol Prime Medicine, Inc. [PRME] 3. Date of Earliest Transaction (Month/Day/Year)						Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) below)		
8755 WEST HIGGINS ROAD, SUITE 1025				10/24/2022								
(Street) CHICAGO IL 60631				nendment, Date of C	Original F	Filed (I	Month/Day/Year)	6. Indiv	Form filed by C	oup Filing (Check A One Reporting Per More than One Re	son
(City)	(State)	(Zip) Table I - Noi	n-Derivative	Securities Acq	uired,	Dis	posed of, or	Benef	ficially C	Owned		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	Execution Date,		ction Instr.	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		A) or , 4 and 5)	5. Amount of Securities Beneficially Own Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(instr. 4)
Common Stock			10/24/2022		С		5,728,297	A	(1)	5,728,297	I	By ARCH Venture Fund X, L.P.(2)(3)
Common Stock			10/24/2022		С		5,728,297	A	(1)	5,728,297	I	By ARCH Venture Fund X Overage, L.P.(3)(4)
												By ARCH

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Р

400,000

400,000

\$17

\$17

A

6,128,297

6,128,297

Venture Fund X, L.P.(2)(3)(5)

 $Fund \; X$ Overage, L.P.⁽²⁾⁽³⁾⁽⁶⁾

By ARCH Venture

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Deri Seci Acq Disp	umber of vative urities uired (A) or oosed of (D) tr. 3, 4 and	6. Date Exerc Expiration Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	tive derivative sy Securities	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Series A Convertible Preferred Stock	(1)	10/24/2022		С			16,666,667	(1)	(1)	Common Stock	5,361,122	\$0	0	I	By ARCH Venture Fund X, L.P ⁽²⁾⁽³⁾
Series A Convertible Preferred Stock	(1)	10/24/2022		С			16,666,664	(1)	(1)	Common Stock	5,361,122	\$0	0	I	By ARCH Venture Fund X Overage, L.P.(3)(4)
Series B Convertible Preferred Stock	(1)	10/24/2022		С			1,141,474	(1)	(1)	Common Stock	367,175	\$0	0	I	By ARCH Venture Fund X, L.P. ⁽²⁾⁽³⁾
Series B Convertible Preferred Stock	(5)	10/24/2022		С			1,141,474	(5)	(5)	Common Stock	367,175	\$0	0	I	By ARCH Venture Fund X Overage, L.P.(3)(4)

1. Name and Address of Reporting Person*

ARCH Venture Partners X, LLC

(Last) (First) (Middle)

Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	
	ss of Reporting Person		
(Last)	(First)	(Middle)	
8755 WEST HIC	GGINS ROAD, SU	ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	
	ss of Reporting Person re Partners X O		
(Last)	(First)	(Middle)	_
8755 WEST HIC	GGINS ROAD, SU	ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(7in)	_
(City) . Name and Addres	(State) as of Reporting Person	(Zip)	
	re Fund X, L.P.		
(Last) 8755 WEST HIC	(First) GGINS ROAD, SU	(Middle) ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	
	ss of Reporting Person	age, L.P.	
(Last)	(First)	(Middle)	
8755 WEST HIC	GGINS ROAD, SU	ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	
I. Name and Addres	ss of Reporting Person		
(Last)	(First)	(Middle)	
8755 WEST HIC	GGINS ROAD, SU	ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	_
1. Name and Addres Burow Kristin	es of Reporting Person	•	
(Last)	(First)	(Middle)	
8755 WEST HIC	GGINS ROAD, SU	ITE 1025	
Street) CHICAGO	IL	60631	
(City)	(State)	(Zip)	
			_

(Last)	(First)	(Middle)	
8755 WEST HIG	GGINS ROAD, SU	JITE 1025	
(Street)			
CHICAGO	IL	60631	
(City)	(State)	(Zip)	

Explanation of Responses:

- 1. The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date.
- 2. Represents shares held directly by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
- 3. ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by them for Section 16 or any other purpose.
- 4. Represents shares held directly by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
- 5. Reflects shares purchased by ARCH X in the Issuer's initial public offering.
- 6. Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.

Remarks:

/s/ ARCH Venture Fund X, L.P., By: ARCH Venture Partners X, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ ARCH Venture Fund X Overage, L.P., By: ARCH Venture Partners X Overage, L.P., its General Partner, By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ ARCH Venture Partners X, L.P., By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ ARCH Venture Partners X Overage, L.P., By: ARCH Venture Partners X, LLC, its General Partner, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ ARCH Venture Partners X, LLC, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ Keith Crandell, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ Kristina Burow, By: Mark McDonnell, attorney-in-fact	10/26/2022
/s/ Steven Gillis, By: Mark McDonnell, attorney-in-fact	10/26/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).